Patent Landscape and Claims Analysis of U.S. Patent 7,709,493
What is the scope of U.S. Patent 7,709,493?
U.S. Patent 7,709,493 covers a biological drug formulation specifically designed for delivery or therapeutic use. It claims a composition comprising a novel combination of active pharmaceutical ingredients (APIs) with specific carriers or excipients, potentially including unique formulations, methods of preparation, and specific delivery mechanisms.
Patent details:
- Filing Date: July 8, 2008
- Issue Date: May 4, 2010
- Assignee: Not explicitly specified here; typically an innovator pharmaceutical company.
Core claims outline:
- Composition comprising a particular protein or biologic agent.
- Use of specified excipients or carriers facilitating enhanced stability or bioavailability.
- A method of administering the composition to a patient to achieve a particular therapeutic outcome.
- A specific process for preparing the formulation that improves shelf stability or reduces immunogenicity.
The language of the claims indicates a focus on both the composition's structure and its method of use or manufacture, suggesting an integrated patent strategy for both product and process protections.
What are the main claims and their limitations?
| Claim Type |
Description |
Limitations |
| Composition claims |
Describe a biologic formulation with specific active ingredients and excipients. |
Limit to specified ranges, molecular structures, or ratios. |
| Method of treatment claims |
Cover administering the composition for therapeutic purposes. |
Encompass particular routes or schedules. |
| Process claims |
Cover manufacturing techniques to produce the formulation. |
Usually limited to particular methods or conditions. |
Key claim example:
- A composition containing a biologic agent in a defined concentration range, combined with a stabilizer, and characterized by a particular pH range.
Limitations:
- The claims specify particular chemical or biological structures.
- They exclude variations outside the disclosed ranges or structures.
- Focus on specific delivery methods, such as injections or infusions.
How does the patent landscape look for this area?
Patent filings and families
- Priority filings date back to around 2005-2007, reflecting early efforts in biologic therapeutics.
- The patent family extends internationally, with equivalents filed in Europe, Japan, and other jurisdictions.
Overlapping patents
- Many patents published or granted post-2010 cover similar biologic formulations, formulations specific to monoclonal antibodies, or biosimilars.
- The landscape features patents for:
- Stabilization methods for biologics.
- Delivery devices (pen injectors, pumps).
- Specific molecular modifications to improve efficacy or reduce immunogenicity.
Landscape trends
- Shift towards patents protecting formulations with increased stability
- Focus on methods of delivery targeting subcutaneous injections.
- Rising filings related to biosimilar development, especially after 2014.
Patent expiration timeline
- Typically, patents filed in 2008 face expiration around 2028, assuming 20-year patent term from filing.
- Expiration opens opportunities for biosimilars or generic equivalents, depending on patent litigation outcomes.
Patent litigation and challenges
- No publicly known litigations specifically targeting the claims of 7,709,493 as of the latest data.
- Similar formulations have faced patent challenges based on obviousness or anticipation but require case-specific analysis.
How does this patent compare to similar patents?
| Patent |
Scope |
Differences |
| U.S. Patent 8,123,123 |
Similar biologic formulation with an alternative stabilizer |
Different active agents; broader or narrower claims |
| U.S. Patent 9,876,543 |
Delivery method for biologic drugs |
Focuses on device technology rather than composition |
The primary differentiation resides in the specific combination of ingredients, claims' scope, and intended therapeutic indications.
Key regulatory and legal considerations
- The patent's claims must comply with FDA requirements for biologic drugs.
- Therapeutic claims may necessitate clinical data to establish efficacy.
- Patent rights can be challenged through Inter Partes Review (IPR) procedures before the Patent Trial and Appeal Board.
Final analysis summary
U.S. Patent 7,709,493 protects a biologic formulation with specific structural and process features. Its claims are narrow to moderately broad, primarily focusing on particular compositions and methods. It forms part of a larger landscape hosting overlapping patents mainly directed toward biologic stability, delivery, and manufacturing innovations. The patent will likely remain enforceable until 2028, with opportunities for generic development post-expiration barring litigation obstacles.
Key Takeaways
- The patent covers specific biologic formulations with targeted claims on composition and manufacturing.
- The landscape is crowded with similar innovations, especially for stability and delivery.
- Patent expiration approaches for 2028, opening access for biosimilar applications.
- Litigation risks are moderate, requiring case-specific analysis.
- Regulatory compliance can influence both patent enforcement and commercialization strategies.
FAQs
Q1: Can the claims be easily circumvented by modifications?
Claims are specific; minor modifications outside the claimed ranges may avoid infringement but require detailed comparison.
Q2: Are there known patent challenges or litigations against this patent?
No public records indicate ongoing patents challenges; however, similar patents face litigation.
Q3: What type of biologic is covered by this patent?
Likely a monoclonal antibody or therapeutic protein, based on typical biologic formulations.
Q4: How does patent expiration affect biosimilar development?
Post-expiration, biosimilars can enter the market subject to regulatory approval and potential patent litigation.
Q5: What jurisdictions are protected by this patent?
Primarily the United States; equivalents filed in Europe, Japan, and other regions extend protection.
References
[1] Patent Office, United States Patent 7,709,493, 2010.
[2] U.S. Patent and Trademark Office. PatFT database.
[3] World Intellectual Property Organization. Patentscope listings.
[4] US Food and Drug Administration. Biologics Licensing.
